BG
LRMR icon

Bellevue Group’s Larimar Therapeutics LRMR Stock Holding History

Bellevue Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-1,667
Closed -$120K – 123
2016
Q2 		$120K Hold
1,667
– – 0.02% 122
2016
Q1 		$134K Buy
+1,667
New +$132K 0.02% 124

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bellevue Group's LRMR Position: Q3 2016 in Review

Bellevue Group sold out of Larimar Therapeutics (LRMR) in Q3 2016, closing a stake of 1,667 shares — an estimated $120K sold.

Bellevue Group first reported a position in LRMR in Q1 2016 and held it in 2 quarters. The position peaked at $134K in Q1 2016. 77 funds tracked by Wall St. Rank hold LRMR as of Q3 2016.

  • Bellevue Group reported no remaining Larimar Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Bellevue Group sold 1,667 Larimar Therapeutics shares in Q3 2016, an estimated $120K.
  • Bellevue Group first reported a position in Larimar Therapeutics in Q1 2016 and held it in 2 quarters.
  • Bellevue Group's Larimar Therapeutics position peaked at $134K in Q1 2016.
  • 77 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q3 2016.

Based on Bellevue Group's 13F filing for Q3 2016, filed 10 Nov 2016.